Clinical Trial

Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 27, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary objective: • To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients. Secondary objectives: • To assess the efficacy, safety, and biomarker changes of 8 mg Aflibercept using a modified fixed-interval dosing regimen over 12 months in treatment-naïve nAMD patients.
Trial Details
NCT Number NCT07728981
Lead Sponsor Tianjin Medical University Eye Hospital
Collaborators: Hebei General Hospital, Shijiazhuang People's Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Shanxi Eye Hospital
Conditions Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Enrollment 49 participants
Start Date 2026-07-25
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27